Who are Conventional Asthma Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fluticasone and salmeterol, Budesonide/formoterol Turbuhaler, FF, Budesonide / Formoterol, RELVAR/BREO, Symbicort Turbohaler without Turbo+.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-asthma-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Conventional Asthma Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conventional Asthma Therapy (Conventional Asthma Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist). Area: Respiratory/Pulmonology.

phase 3 Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist) Glucocorticoid receptor; beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Conventional Asthma Therapy (Conventional Asthma Therapy) — AstraZeneca. Conventional asthma therapy typically combines inhaled corticosteroids to reduce airway inflammation with short-acting beta-2 agonists for acute bronchospasm relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Conventional Asthma Therapy TARGET	Conventional Asthma Therapy	AstraZeneca	phase 3	Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist)	Glucocorticoid receptor; beta-2 adrenergic receptor
fluticasone and salmeterol	fluticasone and salmeterol	University of Chicago	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide/formoterol Turbuhaler	Budesonide/formoterol Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
FF	FF	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide / Formoterol	Budesonide / Formoterol	Brigham and Women's Hospital	marketed	Inhaled corticosteroid / long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
RELVAR/BREO	RELVAR/BREO	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbohaler without Turbo+	Symbicort Turbohaler without Turbo+	Istituto per la Ricerca e l'Innovazione Biomedica	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy (inhaled corticosteroid + short-acting beta-2 agonist) class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional Asthma Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-asthma-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing